Published in Pigment Cell Melanoma Res on June 06, 2014
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | NCT00949702
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00
Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma. J Biol Chem (2015) 0.92
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep (2015) 0.81
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget (2016) 0.79
miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A (2016) 0.78
MicroRNAs in melanoma development and resistance to target therapy. Oncotarget (2017) 0.78
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget (2017) 0.76
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol (2015) 0.76
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res (2015) 0.76
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia. Int J Oncol (2015) 0.75
Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway. Mol Cancer Res (2015) 0.75
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell Int (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
On the origin of cancer cells. Science (1956) 49.55
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol (2005) 7.07
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Energy metabolism in tumor cells. FEBS J (2007) 5.16
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene (2007) 4.80
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol (2004) 3.46
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A (2011) 2.76
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
KSR: a MAPK scaffold of the Ras pathway? J Cell Sci (2001) 1.90
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
The significance of mitochondrial toxicity testing in drug development. Drug Discov Today (2007) 1.56
Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther (2008) 1.52
Molecular pathways: HER3 targeted therapy. Clin Cancer Res (2014) 1.41
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 1.16
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene (2011) 1.10
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res (2013) 1.02
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol (2013) 0.92
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res (2014) 0.89
The oxidative phosphorylation system in mammalian mitochondria. Adv Exp Med Biol (2012) 0.89
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42
Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res (2009) 2.36
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem (2005) 1.88
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene (2005) 1.83
Anchorage-dependent ERK signaling--mechanisms and consequences. Curr Opin Genet Dev (2002) 1.50
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res (2010) 1.39
Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res (2006) 1.36
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res (2009) 1.21
TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res (2012) 1.20
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res (2010) 1.07
FOXD3 regulates migration properties and Rnd3 expression in melanoma cells. Mol Cancer Res (2011) 1.05
Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem (2003) 1.03
SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J Biol Chem (2012) 1.01
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression. J Biol Chem (2006) 0.98
Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell (2008) 0.97
In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res (2013) 0.97
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res (2014) 0.89
alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell Melanoma Res (2010) 0.88
The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol (2010) 0.86
Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res (2014) 0.82
Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations. Adv Pharmacol (2012) 0.82
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res (2011) 0.81
Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res (2012) 0.80
Finding the root of the problem: the quest to identify melanoma stem cells. Front Biosci (Schol Ed) (2011) 0.78
Game of isoforms: PI3K β-sparing inhibitor is coming. Pigment Cell Melanoma Res (2015) 0.77
A STATement on vemurafenib-resistant melanoma. J Invest Dermatol (2013) 0.77
Paying "particle" attention to novel melanoma treatment strategies. J Invest Dermatol (2010) 0.76
Axl of evil? J Invest Dermatol (2011) 0.75
The melanoma field with dendritic roots. Pigment Cell Melanoma Res (2016) 0.75
Mind the BAP. Pigment Cell Melanoma Res (2011) 0.75
American journal of cancer research: editorial board (2011). Am J Cancer Res (2011) 0.75
The Yin-Yang of RAF inhibitors. Pigment Cell Melanoma Res (2012) 0.75